CellCentric raises $220M to get multiple myeloma pill to market
CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech has collected a $220 million Series D to finish its ...
Will West, CellCentric CEO May 6, 2026 07:00 AM EDT FinancingStartups CellCentric raises $220M to get multiple myeloma pill to market Kyle LaHucik Biotech Correspondent CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that